Pardes Biosciences, Inc. (PRDS)
Market Cap | 118.22M |
Revenue (ttm) | n/a |
Net Income (ttm) | -107.38M |
Shares Out | 61.73M |
EPS (ttm) | -11.23 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 51,692 |
Open | 2.00 |
Previous Close | 2.01 |
Day's Range | 1.87 - 2.00 |
52-Week Range | 0.75 - 13.01 |
Beta | n/a |
Analysts | Buy |
Price Target | 10.54 (+450.39%) |
Earnings Date | n/a |
About PRDS
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for PRDS stock is "Buy." The 12-month stock price forecast is $10.54, which is an increase of 450.39% from the latest price.
News

Pardes Biosciences to Present at SVB Securities Global Biopharma Conference
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acti...

RM LAW Announces Investigation of Pardes Biosciences, Inc.
BERWYN, Pa. , Jan. 30, 2023 /PRNewswire/ -- RM LAW, P.C.

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board
BOSTON--(BUSINESS WIRE)--Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Came...

Pardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
Phase 2 trial evaluating PBI-0451 for treatment of COVID-19 ongoing, with data expected in first quarter of 2023 Phase 2 trial evaluating PBI-0451 for treatment of COVID-19 ongoing, with data expected...

Pardes Biosciences to Present at Jefferies London Healthcare Conference
CARLSBAD, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acti...

Pardes Biosciences Appoints Laurie Smaldone Alsup, M.D. and John C.
CARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel oral anti...

Pardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2 Infections
Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral activity, safety, and efficacy of PBI-0451 versus placebo

Pardes Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
CARLSBAD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel direct-ac...

Pardes Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
CARLSBAD, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug can...

Pardes Biosciences to Present at Jefferies Global Healthcare Conference
CARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acti...

Pardes Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-actin...

Pardes Biosciences Reports Full Year 2021 Financial Results and Provides Business Update
CARLSBAD, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-act...

Pardes Biosciences to Present at the International Conference On Antiviral Research 2022
CARLSBAD, Calif. , March 21, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-acti...

Pardes Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CARLSBAD, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-actin...

Pardes Biosciences to Present at Cowen Healthcare Conference
CARLSBAD, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-actin...

Pardes Biosciences Appoints Thomas G. Wiggans to CEO and Chairman of the Board
Mr. Wiggans brings over 40 years of biopharmaceutical industry experience, including over 25 years in chief executive leadership roles with multiple successful acquisitions. His expertise will be bene...

Pardes Biosciences Shares Early Data From COVID-19 Study
Pardes Biosciences Inc's (NASDAQ: PRDS) has presented interim data from its ongoing PBI-0451 Phase 1 trial in healthy adult volunteers at the Conference on Retroviruses and Opportunistic Infections (C...

Pardes Biosciences Presents Interim Clinical Data from Ongoing PBI-0451 Phase 1 Trial Supporting the Potential of PBI-0451 as a Stand-Alone Oral Regimen for COVID-19 at Conference on Retroviruses and Opportunistic Infections 2022
PBI-0451 administered twice-daily as a stand-alone agent achieves and maintains PK exposures anticipated to provide potent antiviral activity against SARS-CoV-2

Pardes Biosciences to Host Virtual Investor Event
Company to host conference call and webcast at 3 p.m. PT on Tuesday, February 15, 2022 Company to host conference call and webcast at 3 p.m. PT on Tuesday, February 15, 2022

Pardes Biosciences to Present Clinical Data from Ongoing PBI-0451 Phase 1 Trial at Conference On Retroviruses And Opportunistic Infections 2022
CARLSBAD, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral ant...

Pardes Biosciences Clears IND Application For Oral Antiviral Candidate For COVID-19
The FDA has signed off Pardes Biosciences Inc's PRDS Investigational New Drug (IND) application for PBI-0451 for COVID-19. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Pardes Biosciences Announces FDA Clearance of IND Application for PBI-0451, an Oral Antiviral Drug Candidate for the Treatment and Prevention of SARS-CoV-2 Infections
CARLSBAD, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral ant...

Pardes Biosciences to Present at J.P. Morgan Healthcare Conference
CARLSBAD, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral ant...

Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19
Ongoing Phase I trial shows potential for stand-alone, unboosted agent against COVID-19

FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections
SAN FRANCISCO & LARKSPUR, Calif.--(BUSINESS WIRE)--FSII and Pardes Biosciences move towards merger with the goal of tackling COVID-19 via an oral antiviral.